Pfizer's RSV Vaccine Shows Sustained Efficacy in Older Adults

After two seasons, Pfizer's Abrysvo vaccine maintains effectiveness against severe RSV, with no new adverse events reported.

Pfizer's Abrysvo vaccine for RSV shows sustained efficacy in older adults across two seasons, with a 77.8% effectiveness against severe lower respiratory tract disease after the second season.
The vaccine's effectiveness against less severe forms of the disease slightly decreased from 65.1% after the first season to 55.7% after the second.
No new adverse events were reported after the second season, maintaining a consistent safety profile.
The FDA approved Abrysvo for preventing RSV in older adults in May 2023 and for use in pregnant women to protect infants last year.
A CDC advisory panel is considering whether seniors should receive RSV shots annually or every other year, with implications for the market and competitors.